Valsartan/Hydrochlorothiazide Sandoz 320 mg / 12.5 mg Norway - Norwegian - Statens legemiddelverk

valsartan/hydrochlorothiazide sandoz 320 mg / 12.5 mg

sandoz - københavn - valsartan / hydroklortiazid - tablett, filmdrasjert - 320 mg / 12.5 mg

Valsartan/Hydrochlorthiazid Actavis 320 mg / 12.5 mg Norway - Norwegian - Statens legemiddelverk

valsartan/hydrochlorthiazid actavis 320 mg / 12.5 mg

actavis group ptc ehf - valsartan / hydroklortiazid - tablett, filmdrasjert - 320 mg / 12.5 mg

Valsartan/Hydrochlorthiazid Actavis 320 mg / 25 mg Norway - Norwegian - Statens legemiddelverk

valsartan/hydrochlorthiazid actavis 320 mg / 25 mg

actavis group ptc ehf - valsartan / hydroklortiazid - tablett, filmdrasjert - 320 mg / 25 mg

Xarelto European Union - Norwegian - EMA (European Medicines Agency)

xarelto

bayer ag - rivaroksaban - arthroplasty, replacement; venous thromboembolism - antithrombotic agents - xarelto, co-gis med acetylsalisylsyre (asa) alene eller sammen med asa pluss clopidogrel eller tiklopidin, er indikert for forebygging av atherothrombotic hendelser hos voksne pasienter etter et akutt koronar syndrom (acs) med forhøyet ved biomarkører. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. forebygging av venøs tromboembolisme (vte) hos voksne pasienter som gjennomgår valgfri hofte- eller kneutskifting. behandling av dyp venetrombose (dvt) og lungeemboli (pe), og forebygging av tilbakevendende dvt og pe i voksne. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Alea 20 mg / 5 mg Norway - Norwegian - Statens legemiddelverk

alea 20 mg / 5 mg

menarini international o.l. sa - olmesartanmedoksomil / amlodipinbesilat - tablett, filmdrasjert - 20 mg / 5 mg

Alea Comp Norway - Norwegian - Statens legemiddelverk

alea comp

menarini international o.l. sa - olmesartanmedoksomil / amlodipinbesilat / hydroklortiazid - tablett, filmdrasjert - 20 mg / 5 mg / 12.5 mg

Benetor 20 mg Norway - Norwegian - Statens legemiddelverk

benetor 20 mg

menarini international o.l. s.a. - olmesartanmedoksomil - tablett, filmdrasjert - 20 mg

Benetor Comp 20 mg / 12.5 mg Norway - Norwegian - Statens legemiddelverk

benetor comp 20 mg / 12.5 mg

menarini international o.l. s.a. - olmesartanmedoksomil / hydroklortiazid - tablett, filmdrasjert - 20 mg / 12.5 mg

Carvedilol Hexal 6.25 mg Norway - Norwegian - Statens legemiddelverk

carvedilol hexal 6.25 mg

hexal a/s - karvedilol - tablett - 6.25 mg

Carvedilol Hexal 12.5 mg Norway - Norwegian - Statens legemiddelverk

carvedilol hexal 12.5 mg

hexal a/s - karvedilol - tablett - 12.5 mg